Anpac Biomedical Technology Co., Ltd. (“Anpac Bio”), a company engaged in early detection of cancer, recently announced that it had received the first payment from a Malaysian customer at the end of February 2023. Biotech has previously signed an equipment purchase contract for the purchase of cancer detection equipment from Anpac Biotech, with a total amount of approximately 10 million yuan (US$1.5 million). The cancer detection equipment is developed and manufactured based on the company’s new multi-cancer detection patented technology – “Cancer Differentiation Analysis Technology” (hereinafter referred to as “CDA”). As the first important sales of Anpac’s cancer detection equipment in Southeast Asia, it is another milestone for Anpac. It marks that Anpac has officially entered the global cancer detection equipment market, and also confirms that Anpac has officially entered the global cancer detection equipment market. Biotech’s new technologies, reputation and ability to penetrate vast global markets. In addition to

Anpac Biomedical Technology Co., Ltd. (hereinafter referred to as “Anpac Bio”) is a biotechnology company listed on Nasdaq that engages in early detection of cancer. Anpac Biotech has two qualified medical laboratories in China. A 2021 market research report by Frost & Sullivan, an authoritative U.S. market research company, shows that Anpac Biotech ranks first in both commercial sample size and total sample size for early screening of multiple (pan) cancers. No. 1 in the world (cumulative as of January 2021). A large number of clinical trials and years of cancer risk assessment follow-up results show that Anpac Biotech’s Cancer Differentiation Analysis (CDA) technology and platform can detect the risk of more than 20 types of cancer with high sensitivity and specificity. < Online paper release screenshot > The Clinical Research Center of Shanghai Jiao Tong University School of Medicine (“Clinical Research Center of Shanghai Jiao Tong University School of

From July 15 to 17, 2022, the ZAODX World Early Cancer Screening Conference, focusing on the research and development and transformation and application of global early screening cutting-edge technologies, was successfully held in Guangzhou. The conference focused on the three major perspectives of “world pattern”, “China exploration” and “solutions” , conduct in-depth discussions around the three major aspects of “technological power”, “productivity” and “market power”, build a top global communication platform, and help industries improve their global cooperation capabilities and market transformation and application capabilities of scientific and technological achievements. Dr. Yu Chang, founder of Anpac Biotechnology, was invited to participate in a roundtable discussion at the “Multi-omics and Multi-Cancer Liquid Biopsy Frontier Forum” on July 15, and together with industry experts and scholars focused on “Multi-omics and Multi-Cancer” “Opportunities and Challenges of Liquid Biopsy” will be discussed as the core to jointly promote the development of the early cancer

Abstract: The academic paper “Clinical Experiments and Results of the Application of Innovative Biophysics-based CDA Technology in Efficacy Evaluation of Lung Cancer” written by Anpac Biotech in collaboration with the School of Life Sciences of Fudan University and Shanghai Changhai Hospital was approved by the American Association for Cancer Research. (AACR) accepted, and will be presented and published as a poster at the 113th American Association for Cancer Research (AACR) Annual Meeting on April 12, 2022. This paper announced the latest important results of clinical verification of the Cancer Differentiation Analysis Technology (CDA) developed by Anpac Bio-Innovation for the evaluation of efficacy in lung cancer. Based on the correlation statistics and analysis of CDA detection data collected during treatment of 686 lung cancer patients and the clinical response (efficacy) of these lung cancer patients to lung cancer treatment, it was initially verified that CDA data and clinical response have a

Shangguan News Report: All cancer categories have relatively high specificity, above 95%, indicating that this blood testing technology is suitable for cancer screening in the general population. Recently, the Clinical Research Center of Shanghai Jiao Tong University School of Medicine and Anpac Biotech, together with experts from the Children’s Hospital of Fudan University, Shanghai Tongren Hospital and other units, published an article introducing a new type of cancer in the international medical journal “Molecular Diagnostics Expert Review” The paper on screening methods provides a theoretical basis for the application of cancer risk assessment (CDA) technology in large-scale cancer screening, allowing multiple cancers to be detected early with low-cost blood tests, allowing patients to receive early treatment. Publish papers online Due to high costs and immature methods, routine health examinations currently often lack effective cancer screening tests. In response to this pain point, CDA technology has developed rapidly in recent years